Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.
Interventions
DRUGZevalin
Zevalin administered intravenous infusion.
DRUGY-90-Zevalin
Y-90-Zevalin administered by intravenous infusion.
DRUGRituximab
Rituximab administered by intravenous infusion.
DRUGIn-111 Zevalin
In-111-Zevalin administered by intravenously.
Sponsors
Spectrum Pharmaceuticals, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participant was 60-years of age or older at time of randomization 2. Histologically confirmed Ann Arbor stage II, III, or IV diffuse large B-cell lymphoma (DLBCL); or follicular lymphoma (FCL) Grade 3B according to the Revised European American lymphoma (REAL)/ World health organization (WHO) classification (from initial diagnosis made prior to starting R-CHOP therapy. Results from a pre R-CHOP marrow shall be available for review. 3. Local pathology review confirming the DLBCL diagnosis and cluster of differentiation 20 (CD20) positivity, and no evidence of DLBCL in bone marrow upon confirmation of complete remission (CR). 4. A paraffin block or original slides available for confirmatory pathology review. Participants may be randomized based on the local pathology result. 5. Age-adjusted international prognostic index (IPI) of 1, 2, or 3. The age-adjusted IPI was defined by one point for Lactate dehydrogenase (LDH) \> upper limit of normal (ULN); Stage III or IV; and Karnofsky performance status \<80% or WHO/ eastern cooperative operations group (ECOG) performance status \>1. 6. First-line treatment of DLBCL must have been 6 cycles of standard R-CHOP21, R-CHOP14 or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) chemotherapy. Participants who received pre-phase therapy for the purpose of improving performance status prior to initiating R-CHOP are eligible. 7. Complete remission (CR) according to the International Workshop Response Criteria for non-Hodgkin's lymphoma (NHL) described by Cheson et al after first-line treatment. Computerized tomography (CT) scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of chemotherapy. Applicability of the neck CT means that the participant had involvement of the neck region by palpation / physical examination at first diagnosis. 8. A negative Fluorine-18-deoxyglucose positron emission tomography (FDG-PET) scan confirming complete response, with negative defined as a score of 1-3 on the Deauville 5-point scale used to quantify radionucleotide density in PET scans as determined locally (Morschhauser 200735). 9. Bone marrow cellularity greater than 15%, no evidence of myelodysplasia morphologically and no evidence of involvement with lymphoma either at the pre R-CHOP marrow or on repeat assessment pre-Zevalin. After completing R-chemotherapy, a repeat marrow is required for participant randomized to the Zevalin arm only. 10. A world health organization/eastern cooperative oncology group (WHO/ECOG) performance status of 0, 1 or 2. 11. Adequate hematopoietic functions: Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/ liter (L), Hemoglobin (Hgb) ≥ 9 g/dL, Platelets ≥ 100 x 10\^9/L. 12. Life expectancy of 6 months or longer. 13. Written informed consent obtained according to local guidelines.
Exclusion criteria
1. Presence of any other malignancy or history of prior malignancy within 5 years of study entry. Within 5 years, participants treated for Stage I or II cancers are eligible provided they have a life expectancy of \> 5 years. The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ cervical cancer. 2. Prior radioimmunotherapy, including radiation therapy for Non-Hodgkin's lymphoma) NHL, or any other NHL therapy. 3. Presence of primary gastric, central nervous system (CNS), or testicular lymphoma at first diagnosis. 4. Histological transformation of low-grade NHL. 5. Active hepatitis B or C. 6. Known history of human immunodeficiency virus (HIV) infection. 7. Abnormal liver function: total bilirubin \> 2 × ULN unless secondary to Gilbert disease. 8. Abnormal renal function: serum creatinine \> 2.0 × ULN. 9. Non-recovery from the toxic effects of chemotherapy to \< grade 2, or interfering with Zevalin treatment. 10. Known hypersensitivity to murine or chimeric antibodies or proteins. 11. Granulocyte-colony stimulating factor (G-CSF) or Granulocyte macrophage-colony stimulating factor (GM-CSF) therapy within 4 weeks prior to Zevalin or observation. 12. Concurrent severe and/or medically uncontrolled disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study. 13. Treatment with investigational drugs less than 4 weeks prior to Zevalin or observation. 14. Major surgery less than 4 weeks prior to Zevalin or start of observation. 15. Concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment. Participants on a chronic dose of prednisone for a medical condition (e.g. Asthma or autoimmune disease) less than or equal to 20 milligram (mg) daily, stable for 4 weeks, are permissible. 16. Unwillingness or inability to comply with the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) for Living Participants | From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years) | OS was the time from randomization to death. In living participants, survival time was censored on the last date that participants were known to be alive. OS for living participant was calculated as (end of study date/last visit date - randomization date)+ 1/30.4375. Overall Survival was summarized separately for living participants as only few participants died in this study. |
| Overall Survival for Death | From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years) | OS was the time from randomization to death. OS for death calculated as (date of death - randomization date)+ 1/30.4375. Overall Survival was summarized separately for participants who were died as only few participants died in this study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years) | PFS was defined as the time interval between the date of randomization and the date of relapse or death from any cause. |
| Overall Survival Rate at 24 Months | 24 Months | The OS rate at 24-month defined as the percentage of all randomized participants who died within 24 months of randomization. |
Countries
Australia, Austria, Belgium, Canada, France, Ireland, Israel, Italy, Netherlands, Puerto Rico, Spain, United Kingdom, United States
Participant flow
Recruitment details
A total of 79 participants were enrolled into the study from 19 Apr 2012 to 23 Oct 2014.
Participants by arm
| Arm | Count |
|---|---|
| Zevalin Participants received rituximab 250 mg/m\^2 by intravenous infusion on Day 1. If required by the governing regulatory agency, rituximab was to be followed 4 hours later by In-111-Zevalin 5.0 mCi on Day 1. And on Days 7-9: participants received rituximab 250 mg/m\^2 by intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in participants with a platelet count in 100,000/μL to 149,000/μL). | 36 |
| Observation Participants who were randomized in this arm group did not receive any anti-lymphoma therapy unless they had a relapse of their disease | 43 |
| Total | 79 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 1 | 2 |
| Overall Study | Other | 0 | 1 |
| Overall Study | Sponsor discretion | 28 | 28 |
| Overall Study | Withdrawal by Subject | 1 | 4 |
Baseline characteristics
| Characteristic | Zevalin | Observation | Total |
|---|---|---|---|
| Age, Continuous | 69 years STANDARD_DEVIATION 1.02 | 71 years STANDARD_DEVIATION 1.06 | 70 years STANDARD_DEVIATION 0.75 |
| Sex: Female, Male Female | 20 Participants | 22 Participants | 42 Participants |
| Sex: Female, Male Male | 16 Participants | 21 Participants | 37 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 36 | 2 / 43 |
| other Total, other adverse events | 21 / 36 | 7 / 43 |
| serious Total, serious adverse events | 8 / 36 | 3 / 43 |
Outcome results
Primary
Overall Survival for Death
OS was the time from randomization to death. OS for death calculated as (date of death - randomization date)+ 1/30.4375. Overall Survival was summarized separately for participants who were died as only few participants died in this study.
Time frame: From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years)
Population: Safety population included all randomized participants classified according to the actual study treatment received, regardless of random assignment. Overall number of participants analyzed signifies participants who died.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Zevalin | Overall Survival for Death | 16.76 months |
| Observation | Overall Survival for Death | 5.82 months |
Primary
Overall Survival (OS) for Living Participants
OS was the time from randomization to death. In living participants, survival time was censored on the last date that participants were known to be alive. OS for living participant was calculated as (end of study date/last visit date - randomization date)+ 1/30.4375. Overall Survival was summarized separately for living participants as only few participants died in this study.
Time frame: From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years)
Population: Safety population included all randomized participants classified according to the actual study treatment received, regardless of random assignment. Overall number of participants analyzed signifies participants who were alive.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Zevalin | Overall Survival (OS) for Living Participants | 8.90 months |
| Observation | Overall Survival (OS) for Living Participants | 6.14 months |
Secondary
Overall Survival Rate at 24 Months
The OS rate at 24-month defined as the percentage of all randomized participants who died within 24 months of randomization.
Time frame: 24 Months
Population: Data for this outcome measure was not collected and analyzed due to early termination of study for sponsor business decision.
Secondary
Progression-Free Survival (PFS)
PFS was defined as the time interval between the date of randomization and the date of relapse or death from any cause.
Time frame: From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years)
Population: Data for this outcome measure was not collected and analyzed due to early termination of study for sponsor business decision.